Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: SOPHiA GENETICS SA

Market Cap 360M 310M 285M 268M 503M 34.01B 508M 3.37B 1.31B 16.65B 1.35B 1.32B 57.71B P/E Ratio 2026 *
-5.52x
P/E Ratio 2027 * -7.21x
Enterprise Value 360M 310M 285M 268M 503M 34.01B 508M 3.37B 1.31B 16.65B 1.35B 1.32B 57.71B EV / Sales 2026 *
3.85x
EV / Sales 2027 * 3.2x
Free-Float
73.68%
Yield 2026 *
-
Yield 2027 * -
1 day-1.64%
1 week-10.00%
Current month-3.27%
1 month+4.02%
6 months+5.08%
Current year+6.70%
1 week 4.14
Extreme 4.14
4.46
1 month 3.94
Extreme 3.94
4.6
Current year 3.46
Extreme 3.46
4.82
1 year 3.34
Extreme 3.34
4.82
3 years 2.08
Extreme 2.08
5.1
5 years 2.08
Extreme 2.08
5.1
10 years 2.08
Extreme 2.08
5.1
Manager TitleAgeSince
Chief Executive Officer 47 01/01/2011
Director of Finance/CFO 64 05/11/2024
President 46 05/11/2024
Director TitleAgeSince
Director/Board Member 74 01/06/2020
Director/Board Member 57 01/06/2014
Director/Board Member 62 01/03/2021
Change 5-day change 1-year change 3-year change Capi.($)
-1.17%-10.00% - - 360M
-0.59%-3.99%-43.43%-19.53% 26.34B
-0.27%-0.92%-39.33%+148.16% 12.18B
-1.64%-5.96%-9.51%+51.66% 6B
-0.02%+14.72% - - 2.83B
+1.00%-1.55%+37.10%-44.12% 1.82B
-1.88%+0.68% - - 1.74B
+0.17%+6.83%-28.45% - 1.32B
+0.28%-3.00%-33.08%-59.36% 813M
+0.56%-0.46%-29.11%+220.30% 786M
Average -0.44%+0.67%-20.83%+49.52% 5.98B
Weighted average by Cap. -0.54%-1.29%-34.51%+34.30%

Financials

2026 *2027 *
Net sales 93.4M 80.49M 74.12M 69.59M 131M 8.83B 132M 876M 341M 4.32B 351M 343M 14.99B 112M 96.84M 89.18M 83.73M 157M 10.62B 159M 1.05B 411M 5.2B 422M 413M 18.03B
Net income -64.65M -55.71M -51.3M -48.17M -90.44M -6.11B -91.39M -606M -236M -2.99B -243M -237M -10.37B -50.72M -43.71M -40.25M -37.79M -70.96M -4.8B -71.71M -476M -185M -2.35B -190M -186M -8.14B
Net Debt - -
Logo SOPHiA GENETICS SA
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
Employees
415
Date Price Change
16/06/26 4.140 -3.27%
15/06/26 4.280 +2.39%
12/06/26 4.180 -6.28%
11/06/26 4.460 +0.90%
10/06/26 4.420 -3.91%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.010USD
Average target price
8.000USD
Spread / Average Target
+59.68%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!